1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
13 déc. 2022 04h00 HE | AKAMPION
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...
Affimed Logo.jpg
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
12 déc. 2022 10h00 HE | Affimed N.V.
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid...
Affimed Logo.jpg
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
10 déc. 2022 15h00 HE | Affimed N.V.
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL) patients with a differentiated safety profile AFM13...
Affimed Logo.jpg
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
10 déc. 2022 14h20 HE | Affimed N.V.
AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patientsPatients had...
FDA Approves Immunotherapy for mNSCLC Patients in Study Conducted at Florida Cancer Specialists & Research Institute
Recent FDA Approval of Advanced Treatment for Patients with Metastatic Non Small-Cell Lung Cancer (NSCLC) Demonstrates Importance of Participation in Clinical Trials
06 déc. 2022 15h41 HE | Florida Cancer Specialists & Research Institute
Ft. Myers, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- A clinical study conducted with participation by Florida Cancer Specialists & Research Institute, LLC (FCS) has led to FDA approval of a new...
Gene Therapy in Oncology Market Report 2022: Growing Investment and Funding for Product Development Bolsters Sector
30 nov. 2022 05h38 HE | Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "Gene Therapy in Oncology Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Therapy Type (Oncolytic Virotherapy, Gene Transfer, Gene...
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
28 nov. 2022 08h00 HE | Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
22 nov. 2022 09h10 HE | Aridis Pharmaceuticals, Inc.
The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 ...
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
21 nov. 2022 16h05 HE | Adagene Inc.
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today...
PDS Biotech Logo.png
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress
21 nov. 2022 08h00 HE | PDS Biotechnology Corporation
Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform Dr. Siva Gandhapudi, Director of...